LabCorp initiated with an Underperform at Wolfe Research. Wolfe Research started LabCorp with an Underperform rating and $150 price target, citing concerns about the 2021 impact of PAMA and exposure to patient collections.
https://thefly.com/landingPageNews.php?id=2887449
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.